Table 1.
Treatment schedule
| Day | −10 | −9 | −8 | −7 | −6 | −5 | −4 | −3 | −2 | −1 | 0 | +1 | +8 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gemcitabine | Daily | X | X | X | X | X | X | |||||||
| 3-dose | X | X | X | |||||||||||
| 2-dose | X | X | ||||||||||||
| Busulfan | x (test) | X | X | X | X | |||||||||
| Melphalan | X | X | ||||||||||||
| PBPC | X | |||||||||||||
| Rituximab (CD20+ tumors) | X | X | ||||||||||||
Treatment schedule
| Day | −10 | −9 | −8 | −7 | −6 | −5 | −4 | −3 | −2 | −1 | 0 | +1 | +8 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gemcitabine | Daily | X | X | X | X | X | X | |||||||
| 3-dose | X | X | X | |||||||||||
| 2-dose | X | X | ||||||||||||
| Busulfan | x (test) | X | X | X | X | |||||||||
| Melphalan | X | X | ||||||||||||
| PBPC | X | |||||||||||||
| Rituximab (CD20+ tumors) | X | X | ||||||||||||